포스트 본문영역

좋아요, 댓글, 공유 상태바

어제 북미 최고 권위 증권 소식지 Stock Watch에 나온 우리 회사 관련 기사입니다.

"이스트우드사는 최근 22개의 신제품에 대해서 Health Canada (캐나다의 FDA)에서 허가를 받았습니다. 올해만 총 39개의 신제품을 출시했고, 거의 모두 Health Canada의 허가를 받았습니다. R&D에 강한 회사, 대사증후군 관련 세계 최고의 회사라는 위치를 고수하고자 모든 임직원이 열심히 노력한 결과입니다. "

(기사원문)

EASTWOOD BIO-MEDICAL CANADA INC. (TSX-V: EBM) EASTWOOD BIO-MEDICAL CANADA INC. ANNOUNCES TWENTY-TWO NEW HEALTH CANADA APPROVED PRODUCTS

Eastwood Bio-Medical Canada Inc. has introduced 22 new products approved by Health Canada.

Since early May, 2017, Health Canada granted natural product numbers (NPNs) for the natural health products in the attached table.

Especially noteworthy are Avgi Formula, a demulcent, and Slumber Bouquet, a sleep aid. Made of unique proprietary formulas, the two products were especially researched and developed for the company's markets.

In March, 2017, the company announced the addition of 17 new products. The current addition of 22 new Health Canada-approved products announced today brings the number of new products up to 39 in the first half of 2017 alone.

Yunji Kim, president and chief executive officer of Eastwood Bio-Medical Canada, commented: "Obtaining approvals for new proprietary formulae can be a challenging and complex process. I am very proud of my team for their success in doing so. We aspire to be the foremost company in quality and quantity in developing Health Canada-approved formulas. I believe we are only starting to realize the first achievements of this goal."

On Behalf of the Board,
Yunji Kim
Chairman & CEO
604-247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate","may", "will", "potential", "proposed" and other similar words, or statements that certain events

댓글영역
김명규11월 12일 오후 12:19

엘레오틴 인천모임 김명규리더 연락처.
010 9750 2988.
대사증후군 관련 문의바랍니다.